Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital reduced their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.

Evogene Stock Up 4.7 %

Shares of EVGN stock opened at $1.35 on Friday. Evogene has a 52 week low of $1.20 and a 52 week high of $10.40. The company has a market cap of $7.24 million, a P/E ratio of -0.30 and a beta of 1.36. The business has a 50 day moving average of $1.86 and a two-hundred day moving average of $3.64.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.